Certainly not GLP-1 drugs, who are now set to go mainstream. As the patent expires, the Indian markets will be flush with low-cost options. But, experts warn, indiscriminate jab-hopping may cost you more than you think

But it absolved him of some fraud allegations, finding that he did not “scheme” to mislead investors.